Disease Landscape and Forecast Insights

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/…

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The…

For the estimated 5 million people in the United States with AF, several treatment approaches are used, each with a wide range of pharmacological options. The established guidelines recommend the…

Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis…

Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…

Market Outlook Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for moderate to…

The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone,…

MARKET OVERVIEW The narcolepsy market has been characterized by a lack of available and on-label therapies as well as low diagnosis rates because patients often do not seek treatment; however,…

Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown…

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Children with CD have a more-complicated…

Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen /…

For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil,…